Literature DB >> 32219621

Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis.

Zaw Thet1,2, Alfred K Lam3, Dwarakanathan Ranganathan1,4, Soe Yu Aung5,6, Tien K Khoo7,8.   

Abstract

This review appraises the current literature on carcinogenic risks in anti-neutrophilic cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Patients with AAV are often at increased risk of developing non-melanoma skin carcinomas (NMSCs), haematological malignancies, bladder, breast, lung, prostate, and colorectal carcinomas. Reported cancer incidence in these patients ranged from 10 to 26%. Cancer risks at the time of diagnosis of AAV and disease outcomes along the trajectory of AAV that may lead to chronic kidney disease (CKD); dialysis and transplantation are summarized. Inherent carcinogenic risks as part of immunosuppressive treatment in AAV are further detailed with considerations on specific malignancy risks of therapeutic agents used. Challenges that contribute to malignancy risk include a high relapse rate of AAV and prolonged exposure to immunosuppressants. The incidence of malignancy increases significantly after 5 years of immunosuppressant exposure though risks in the earlier years have also been described. Following renal transplantation, there is limited information available on risk of malignancy. Thoughtful use of immunosuppressants, modification of lifestyle, and environmental factors, as well as adopting appropriate cancer screening will likely influence malignancy risk in individuals with AAV.

Entities:  

Keywords:  ANCA; Cancer; Glomerular nephritis; Malignancy; Vasculitis

Mesh:

Substances:

Year:  2020        PMID: 32219621     DOI: 10.1007/s10067-020-05055-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

1.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; Mary-Jane Guerry; Simona Laurino; Fausta Catapano; Afzal Chaudhry; Kenneth G C Smith; David R W Jayne
Journal:  Arthritis Rheum       Date:  2012-11

2.  Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

Authors:  Jens Thiel; Arianna Troilo; Ulrich Salzer; Theresa Schleyer; Kirsten Halmschlag; Marta Rizzi; Natalie Frede; Ana Venhoff; Reinhard E Voll; Nils Venhoff
Journal:  J Allergy Clin Immunol Pract       Date:  2017-09-12

3.  Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.

Authors:  Emma E van Daalen; Raffaella Rizzo; Andreas Kronbichler; Ron Wolterbeek; Jan A Bruijn; David R Jayne; Ingeborg M Bajema; Chinar Rahmattulla
Journal:  Ann Rheum Dis       Date:  2016-11-29       Impact factor: 19.103

4.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Authors:  Alexandre Karras; Christian Pagnoux; Marion Haubitz; Kirsten de Groot; Xavier Puechal; Jan Willem Cohen Tervaert; Mårten Segelmark; Loic Guillevin; David Jayne
Journal:  Ann Rheum Dis       Date:  2017-05-25       Impact factor: 19.103

6.  Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Authors:  William F Pendergraft; Frank B Cortazar; Julia Wenger; Andrew P Murphy; Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-13       Impact factor: 8.237

7.  Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Authors:  Ana Luisa Calich; Xavier Puéchal; Grégory Pugnet; Jonathan London; Benjamin Terrier; Pierre Charles; Luc Mouthon; Loïc Guillevin
Journal:  J Autoimmun       Date:  2014-04-02       Impact factor: 7.094

8.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Authors:  Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2013-11-15       Impact factor: 19.103

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

10.  Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.

Authors:  Sanjeevan Sriskandarajah; Leif Bostad; Tor Åge Myklebust; Bjørn Møller; Steinar Skrede; Rune Bjørneklett
Journal:  Int J Nephrol       Date:  2017-12-18
View more
  1 in total

Review 1.  New lung mass in a patient with granulomatosis with polyangiitis.

Authors:  Anna Masiak; Jadwiga Fijałkowska; Szymon Nowakowski; Żaneta Smoleńska; Zbigniew Zdrojewski
Journal:  Rheumatol Int       Date:  2020-07-16       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.